Robert Samstein

This phase 2 trial tests a biologic drug called nadunolimab in current or former smokers who have high-risk lung nodules that are not yet ready for surgery. The goal is to see if the drug can shrink these nodules by at least 20% within 3 months, potentially preventing lung cancer…